Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification

Similar Items

• Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
  by: Katsuhiro Yoshimura, MD, et al.
  Published: (2017-01-01)
• The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
  by: Balázs Jóri, et al.
  Published: (2023-09-01)
• Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib
  by: Waleed Kian, et al.
  Published: (2023-02-01)
• Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
  by: Miriam Blasi, et al.
  Published: (2021-03-01)
• Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
  by: Zhu VW, et al.
  Published: (2019-03-01)